Tvardi Therapeutics Inc TVRD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Tvardi Therapeutics to Participate in Chardan’s 10th Annual Healthcare Conference
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
Tvardi Therapeutics to Participate in Upcoming Investor Events
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
Trading Information
- Previous Close Price
- $0.86
- Day Range
- $0.85–0.86
- 52-Week Range
- $0.77–5.69
- Bid/Ask
- $0.83 / $0.86
- Shares Outstanding
- 13.34M
- Market Cap
- $11.53M
- Volume/Avg
- 1,100 / 175,037
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
Valuation
Metric | TVRD |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.97 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | TVRD |
|---|---|
Quick Ratio | 1.73 |
Current Ratio | 1.87 |
Interest Coverage | — |
Quick Ratio
TVRD
Profitability
Metric | TVRD |
|---|---|
Return on Assets (Normalized) | −77.97% |
Return on Equity (Normalized) | −117.88% |
Return on Invested Capital (Normalized) | −122.16% |
Return on Assets
TVRD
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|>f&%$t? | LOCK|gL%K% | $138B | |||
| Moderna Inc MRNA | LOCK|VPCXt>M | LOCK|WwS | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|CjZT^G | LOCK|md<z | $93B | |||
| argenx SE ADR ARGX | LOCK|!Tgj^<B | LOCK|BR | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|n<kBgn | LOCK|H>G | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|l&$!KyR# | LOCK|!&@n | $30B | |||
| Incyte Corp INCY | LOCK|WMD?C^ | LOCK|@&T | $24B | |||
| BioNTech SE ADR BNTX | LOCK|^mLF%s | LOCK|#Ns | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|&L&%yW% | LOCK|L<$@ | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|&#?$s& | LOCK|$% | $15B |
United States